Prevención y tratamiento de la toxicidad de la isoniazida en la terapia de la tuberculosis pulmonar
This paper from the Tuberculosis Chemotherapy Centre, Madras, presents the results of a study designed primarily (a) to assess the efficacy of two preparations -Tab. Aneurin. Co. (a vitamin B compound not containing pyridoxine) and glutamic acid -in preventing the development of peripheral neuropathy during high-dosage (12.5-15.2 mg/kg) isoniazid therapy for pulmonary tuberculosis, and (b) to compare the therapeutic efficacy, once isoniazid neuropathy has developed, of Tab. Aneurin. Co., administered at twice the prophylactic dosage, and a vitamin B-complex preparation containing a small amount of pyridoxine (amounting to 6 mg daily)Tab. Aneurin. Co. was found to be ineffective in preventing peripheral neuropathy, which occurred in five of the 18 patients receiving this preparation, as compared with six of the 18 who received a placebo, calcium gloconate. Glutamic acid appeared to have some prophylactic effect, since only two of the 19 patients receiving it developed the neuropathy, but the difference between the frequency in the glutamic series and that in the placebo series did not attain statistical significanceAs to the therapeutic efficacy of the two vitamin B preparations, Tab. Aneurin. Co., at twice the prophylactic dosage, did not prevent the progression of the neuropathy in five out of seven patients, whereas improvement occurred in eight of the nine patients who received the ...(AU)Publicado en inglés en el Bull. WHO 28(4), 1963
The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis
Showing items related by title, author, creator and subject.
Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia Marchiol, Andrea; Forsyth, Colin; Bernal, Oscar; Valencia Hernández, Carlos; Cucunubá, Zulma; Pachón Abril, Eduin; Vera Soto, Mauricio Javier; Batista, Carolina (2017-12)[ABSTRACT]. Worldwide, over 6 million people are infected with Trypanosoma cruzi, the pathogen that causes Chagas disease (CD). In the Americas, CD creates the greatest burden in disability-adjusted life years of any ...
Baker, Brian J.; Peterson, Brandy; Mohanlall, Jeetendra; Singh, Shanti; Hicks, Collene; Jacobs, Ruth; Ramos, Ruth; Allen, Barbara; Pevzner, Eric (2017-01)Objective. To assess scale-up of recommended tuberculosis (TB)/HIV activities in Guyana and to identify specific strategies for further expansion. Methods. Medical records and clinic registers were reviewed at nine TB ...
Rodríguez, David A.; Verdonck, Kristien; Bissell, Karen; Victoria, Juan José; Khogali, Mohammed; Marín, Diana; Moreno, Ernesto (2016-01)Objective. To measure time between onset of tuberculosis (TB) symptoms and start of treatment, and to identify factors associated with delay in eight Colombian cities. Methods. Operational research with a retrospective ...